io9 OncoGaze™ is an AI platform
for molecular profiling from routine clinical slides. The technology makes it possible to detect genomic biomarkers from digital slides, making access to treatment possible for all patients worldwide.
July 2024
io9 Announces Publication in the Journal of Clinical Oncology Demonstrating Efficacy of OncoGaze™, its Next-Generation AI Platform, Poised to Eliminate Delays and Inequities in Correct First-Line Precision Treatment Selection for Cancer Patients
“Precision medicine has transformed outcomes for cancer patients, but many with advanced cancer who are eligible for precision therapy are not receiving the right first-line treatments because the journey from diagnosis to therapeutic selection is costly, time consuming, and confusing,” said senior author Ludmil Alexandrov, Ph.D., co-founder, chief scientific officer of io9 and professor of bioengineering and professor of cellular and molecular medicine at University of California San Diego.
Equity in cancer care is the future.
Our technologies make precision medicine relevant for every cancer patient. io9 has made key scientific breakthroughs that improve cancer diagnosis, offer new targets for treatment, and that provide new therapeutic approaches to make cancer detection and care more equitable around the globe.
Meet the team.
io9 founders are successful serial entrepreneurs, internationally recognized scientists, and clinical luminaries in the fields of clinical oncology, immuno-oncology, and AI.